DNA Methylation Profiles and Their Diagnostic Utility in BC

Area of Science:

• Epigenetics
• Molecular Biology
• Oncology
• Biomarker Discovery

Background:

• DNA methylation biomarkers offer potential for personalized medicine and breast cancer (BC) diagnosis, particularly in resource-limited settings.
• Identifying reliable epigenetic markers is crucial for early and accurate BC detection.

Purpose of the Study:

• To investigate the frequency of promoter methylation in specific genes within breast cancer tissues.
• To validate the diagnostic utility of these methylation biomarkers in serum for clinical BC detection.
• To assess the association of methylation patterns with different molecular subtypes of BC.

Main Methods:

• Bisulfite sequencing PCR was employed on twelve paired breast cancer and normal tissue specimens.
• Nine genetic probes were designed to analyze promoter methylation frequency in 302 paired BC and normal breast tissue samples.
• Serum samples (n=900) were utilized to validate the diagnostic performance of identified methylation biomarkers.

Main Results:

• High frequencies of promoter methylation were observed for SFN, HOXA11, P16, RARβ, PCDHGB7, hMLH1, WNT5a, HOXD13, and RASSF1a in BC tissues.
• Methylation frequencies of HOXD13 and hMLH1 correlated with BC progression, while HOXD13 and WNT5a showed significantly higher methylation in BC.
• RASSF1a, P16, and PCDHGB7 demonstrated significant sensitivity and specificity as diagnostic biomarkers (P < 0.001); a panel of these three improved diagnostic accuracy (AUC, 0.781).

Conclusions:

• Epigenetic markers in serum hold significant potential for the clinical diagnosis of breast cancer.
• The identified methylation biomarkers, particularly RASSF1a, P16, and PCDHGB7, show promise for BC diagnostics.
• Distinct genetic and epigenetic mechanisms may underlie different molecular subtypes of breast cancer.